Annelieke Pasma1, Adriaan van 't Spijker2, Jolanda J Luime2, Margot J M Walter2, Jan J V Busschbach2, Johanna M W Hazes2. 1. From Department of Rheumatology, Department of Psychiatry, and Section Medical Psychology and Psychotherapy, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, the Netherlands.A. Pasma, MSc; J.J. Luime, PhD; M.J.M. Walter, MSc; J.M.W. Hazes, MD, PhD, Department of Rheumatology; A. van 't Spijker, PhD; J.J.V. Busschbach, PhD, Department of Psychiatry, Section Medical Psychology and Psychotherapy, Erasmus Medical Center, University Medical Center Rotterdam. a.pasma@erasmusmc.nl. 2. From Department of Rheumatology, Department of Psychiatry, and Section Medical Psychology and Psychotherapy, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, the Netherlands.A. Pasma, MSc; J.J. Luime, PhD; M.J.M. Walter, MSc; J.M.W. Hazes, MD, PhD, Department of Rheumatology; A. van 't Spijker, PhD; J.J.V. Busschbach, PhD, Department of Psychiatry, Section Medical Psychology and Psychotherapy, Erasmus Medical Center, University Medical Center Rotterdam.
Abstract
OBJECTIVE: To explore themes associated with adherence in the initiation phase for first-time use of disease-modifying antirheumatic drugs (DMARD) in patients with inflammatory arthritis using focus groups and individual interviews. METHODS: Thirty-three patients were interviewed in focus groups and individual interviews. Interviews were transcribed verbatim and imported into ATLAS.ti software (Scientific Software Development GmbH). Responses that included reasons for adherence or nonadherence in the initiation phase were extracted and coded by 2 coders separately. The 2 coders conferred until consensus on the codes was achieved. Codes were classified into overarching themes. RESULTS: Five themes emerged: (1) symptom severity, (2) experiences with medication, (3) perceptions about medication and the illness, (4) information about medication, and (5) communication style and trust in the rheumatologist. CONCLUSION: Perceptions about medication and the communication style with, and trust in, the rheumatologist were mentioned the most in relation to starting DMARD. The rheumatologist plays a crucial role in influencing adherence behavior by addressing perceptions about medication, providing information, and establishing trust in the treatment plan.
OBJECTIVE: To explore themes associated with adherence in the initiation phase for first-time use of disease-modifying antirheumatic drugs (DMARD) in patients with inflammatory arthritis using focus groups and individual interviews. METHODS: Thirty-three patients were interviewed in focus groups and individual interviews. Interviews were transcribed verbatim and imported into ATLAS.ti software (Scientific Software Development GmbH). Responses that included reasons for adherence or nonadherence in the initiation phase were extracted and coded by 2 coders separately. The 2 coders conferred until consensus on the codes was achieved. Codes were classified into overarching themes. RESULTS: Five themes emerged: (1) symptom severity, (2) experiences with medication, (3) perceptions about medication and the illness, (4) information about medication, and (5) communication style and trust in the rheumatologist. CONCLUSION: Perceptions about medication and the communication style with, and trust in, the rheumatologist were mentioned the most in relation to starting DMARD. The rheumatologist plays a crucial role in influencing adherence behavior by addressing perceptions about medication, providing information, and establishing trust in the treatment plan.
Authors: Kathleen M Andersen; Ayano Kelly; Anne Lyddiatt; Clifton O Bingham; Vivian P Bykerk; Adena Batterman; Joan Westreich; Michelle K Jones; Marita Cross; Peter M Brooks; Lyn March; Beverley Shea; Peter Tugwell; Lee S Simon; Robin Christensen; Susan J Bartlett Journal: J Rheumatol Date: 2019-02-15 Impact factor: 4.666
Authors: Yomei Shaw; Ilinca D Metes; Kaleb Michaud; Julie M Donohue; Mark S Roberts; Marc C Levesque; Judy C Chang Journal: Arthritis Care Res (Hoboken) Date: 2018-03-11 Impact factor: 4.794
Authors: Annelieke Pasma; Charlotte Schenk; Reinier Timman; Adriaan van 't Spijker; Cathelijne Appels; Willemijn H van der Laan; Bart van den Bemt; Robert Goekoop; Johanna M W Hazes; Jan J V Busschbach Journal: PLoS One Date: 2017-02-02 Impact factor: 3.240
Authors: Ayano Kelly; Kathleen Tymms; David J Tunnicliffe; Daniel Sumpton; Chandima Perera; Kieran Fallon; Jonathan C Craig; Walter Abhayaratna; Allison Tong Journal: Arthritis Care Res (Hoboken) Date: 2018-03-24 Impact factor: 4.794
Authors: Alyssa Wohlfahrt; Anarosa Campos; Maura D Iversen; Joshua J Gagne; Elena Massarotti; Daniel H Solomon; Candace H Feldman Journal: PLoS One Date: 2018-07-19 Impact factor: 3.240
Authors: Bart Ph Pouls; Charlotte L Bekker; Sandra van Dulmen; Johanna E Vriezekolk; Bart Jf van den Bemt Journal: JMIR Serious Games Date: 2022-02-18 Impact factor: 3.364
Authors: Annelieke Pasma; Charlotte V Schenk; Reinier Timman; Jan J V Busschbach; Bart J F van den Bemt; Esmeralda Molenaar; Willemijn H van der Laan; Saskia Schrauwen; Adriaan Van't Spijker; Johanna M W Hazes Journal: Arthritis Res Ther Date: 2015-10-08 Impact factor: 5.156